<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Opioid withdrawal: Clinical features, assessment, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Opioid withdrawal: Clinical features, assessment, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Opioid withdrawal: Clinical features, assessment, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin A Sevarino, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew J Saxon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2009707767"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Spontaneous opioid withdrawal occurs when a patient who is physiologically dependent upon opioids reduces or stops opioid use abruptly. Precipitated opioid withdrawal can occur when a patient who is physiologically dependent upon opioids and who has or recently had opioids in their system is administered an opioid antagonist (<a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a>, <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a>, or <a class="drug drug_general" data-topicid="135038" href="/d/drug information/135038.html" rel="external">nalmefene</a>) or an opioid partial agonist (<a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>). Signs and symptoms of opioid withdrawal include drug craving, anxiety, restlessness, gastrointestinal distress, diaphoresis, and tachycardia. Untreated opioid withdrawal frequently results in return to opioid use.</p><p>Patients in opioid withdrawal or seeking to stop an opioid to which they are physiologically dependent can undergo medically supervised opioid withdrawal (also known as detoxification), in which medication is used to reduce the severity of withdrawal symptoms [<a href="#rid1">1</a>].</p><p>This topic describes the clinical manifestations, course, assessment and diagnosis of opioid withdrawal. Medically supervised opioid withdrawal as the first step in treatment of opioid use disorder is described separately. Pharmacotherapy and psychosocial interventions for opioid use disorder are also discussed separately. The management of unplanned withdrawal in the emergency department and opioid withdrawal in adolescents are discussed separately. (See  <a class="medical medical_review" href="/d/html/7808.html" rel="external">"Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"</a> and  <a class="medical medical_review" href="/d/html/306.html" rel="external">"Opioid withdrawal in the emergency setting"</a> and  <a class="medical medical_review" href="/d/html/6505.html" rel="external">"Opioid withdrawal in adolescents"</a> and  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management"</a> and  <a class="medical medical_review" href="/d/html/99647.html" rel="external">"Opioid use disorder: Psychosocial management"</a>.)</p><p class="headingAnchor" id="H2631655063"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Patients presenting for opioid withdrawal management include those with untreated opioid use disorders, those on <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> or <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> maintenance who are ending this treatment voluntarily or not, those currently using opioids who are to be initiated on extended-release <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a>, and those ending chronic opioid treatment for pain management. Supervised opioid withdrawal uses medication to reduce the severity of withdrawal symptoms.</p><p>Supervised withdrawal alone is unlikely to result in sustained abstinence from opioids [<a href="#rid2">2</a>], nor does it address reasons the patient became dependent on opioids or the damage that the addiction has done to relationships, employment, finances, and the mental, physical, and spiritual health of the patient. Without successful transition to follow-up treatment, medications for opioid use disorder (<a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, extended-release <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a>), or supervised withdrawal alone is associated with many harms, including elevated rates of death, incarceration, and infectious disease transmission [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H3443629360"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The signs and symptoms of unmedicated opioid withdrawal include [<a href="#rid5">5-7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal distress</strong> – Abdominal cramps, diarrhea, nausea, and/or vomiting</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flu-like symptoms</strong> – Lacrimation, rhinorrhea, diaphoresis, shivering, and piloerection (goosebumps)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sympathetic nerve and central nervous system arousal</strong> – Mydriasis, mild hypertension, and tachycardia, anxiety and irritability, insomnia, agitation, restless leg syndrome, general restlessness, tremor, and, less frequently, low-grade temperature and tactile sensitivity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Yawning, sneezing, anorexia, dizziness, myalgias/arthralgias, leg cramps and dysthymia</p><p></p><p>There can be significant individual differences in the expression of opioid withdrawal, especially in those experiencing milder symptoms [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H2686621800"><span class="h2">Co-occurring conditions</span><span class="headingEndMark"> — </span>Patients with opioid use disorders have elevated rates of other substance use disorders, especially nicotine (up to 85 percent), and elevated rates of mental disorders (up to 70 percent), especially major depression, panic disorder, generalized anxiety disorder, posttraumatic stress disorder, and antisocial personality disorder [<a href="#rid9">9-11</a>].</p><p>Elevated rates of mental disorders and other substance use disorders are also seen in patients exhibiting nonmedical use of prescribed opioids [<a href="#rid12">12,13</a>] and those with chronic pain treated with opioids [<a href="#rid14">14,15</a>]. A systematic review of 11 studies of patients with nonmedical use of prescription opioids found a pooled prevalence of co-occurring anxiety disorders to be 29 percent and depressive disorders 27 percent, both two to three times the rate found in the general population [<a href="#rid12">12</a>]. The direction of causality for these comorbidities is unknown and likely is a combination of shared vulnerability [<a href="#rid13">13,16</a>], opioid exposure leading to development of comorbid symptoms and diagnoses [<a href="#rid17">17</a>], and comorbid diagnoses elevating the risk to develop physiologic dependence with or without addiction [<a href="#rid18">18,19</a>].</p><p>While it should be expected that the presence of comorbid conditions will make treatment of symptoms in opioid withdrawal more difficult [<a href="#rid20">20</a>], there are few studies that directly address the effect of the comorbidities on the course or severity of opioid withdrawal. An exception is comorbid tobacco use disorder, which has been associated with worse opioid withdrawal symptoms in inpatients treated with <a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">clonidine</a> and <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> taper [<a href="#rid21">21</a>]. High rates (40 percent) of benzodiazepine use in the prior month were reported in those seeking opioid detoxification, with the most commonly cited reason being to control anxiety [<a href="#rid22">22</a>].</p><p>Other co-occurrences that may complicate supervised opioid withdrawal include:</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid alcohol and benzodiazepine withdrawal (see  <a class="medical medical_review" href="/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Expressed suicidal ideation with comorbid cocaine and methamphetamine withdrawal (see  <a class="medical medical_review" href="/d/html/1708.html" rel="external">"Suicidal ideation and behavior in adults"</a> and  <a class="medical medical_review" href="/d/html/14839.html" rel="external">"Methamphetamine use disorder: Epidemiology, clinical features, and diagnosis", section on 'Abstinence syndrome'</a> and  <a class="medical medical_review" href="/d/html/7802.html" rel="external">"Cocaine use disorder: Epidemiology, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Personality disorders (see  <a class="medical medical_review" href="/d/html/6617.html" rel="external">"Overview of personality disorders"</a> and  <a class="medical medical_review" href="/d/html/16980.html" rel="external">"Approaches to the therapeutic relationship in patients with personality disorders"</a>)</p><p></p><p>Those who report high levels of pain during opioid withdrawal (58 percent of 814 people who inject drugs) showed increased risk of subsequent nonfatal overdose [<a href="#rid23">23</a>]. In studies of patients with current and prior misuse of prescription opioids, suicidal ideation has been found to be elevated even in patients who do not have active opioid withdrawal [<a href="#rid24">24</a>]. The FDA issued <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F122935%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPN1qFO0qb3jmtkOOsARnS9wv%2BqOeyrsQsHUy0fcKXRh7RZ64Ta786ugOwIE91S0fww%3D%3D&amp;TOPIC_ID=105686" target="_blank">a warning</a> that those who have prescribed opioids for pain suddenly discontinued may experience serious harms including marked withdrawal, uncontrolled pain, psychological stress, and suicide.</p><p class="headingAnchor" id="H2878809650"><span class="h1">COURSE</span><span class="headingEndMark"> — </span>An opioid typically must be consumed daily for three weeks or more for physiologic dependence to develop and for the patient to require medically supervised withdrawal. However, in those previously tolerant to opioids, briefer periods of recurrence of use may trigger withdrawal after shorter periods of use followed by cessation. Withdrawal will only occur in those who have developed tolerance to the opioid.</p><p>Following cessation of opioid use, the precise onset and completion of withdrawal, the order of symptoms, and which symptoms are most prominent can vary prominently among individuals and across opioid drugs [<a href="#rid25">25</a>]. As examples, the duration of the syndrome can range from four to five days for short-term intravenous <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> to two to three weeks for <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>. A rough rule of thumb is that onset of symptoms occurs after two to three times the half-life of the withdrawn opioid. A table provides onset, peak and duration of opioid withdrawal for select opioids  (<a class="graphic graphic_table graphicRef105766" href="/d/graphic/105766.html" rel="external">table 1</a>). The proliferation of fentanyl dependence in individuals not only knowingly using fentanyl, but those using contaminated heroin, oxycodone-pills, methamphetamine, etc has led to the lore that fentanyl withdrawal occurs earlier, is more severe, and is more enduring than from heroin [<a href="#rid26">26</a>]. The lipophilicity of fentanyl leads to distribution into adipose tissue so that later release leads to extended duration of effect, and hence duration of withdrawal. High body mass index (BMI) status appears to correlate with more severe withdrawal scores than an individual’s use status.</p><p>Unmedicated opioid withdrawal can be quite uncomfortable but rarely life threatening, though Takotsubo (stress-induced) cardiomyopathy may be underappreciated [<a href="#rid27">27</a>] and seizures are reported at the case report level [<a href="#rid28">28</a>]. Withdrawal precipitated by medications (eg, antagonists, partial agonists, inverse agonists) is more rapid in onset and often with more severe symptoms, with reports of life-threatening delirium and severe autonomic instability [<a href="#rid29">29,30</a>]. Risks associated with overdose during supervised withdrawal are described separately. (See  <a class="medical medical_review" href="/d/html/7808.html" rel="external">"Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"</a>.)</p><p class="headingAnchor" id="H808669733"><span class="h1">ASSESSMENT</span></p><p class="headingAnchor" id="H1308590390"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>Our initial evaluation of patients at risk of opioid withdrawal includes a substance use history, psychiatric assessment and history, mental status examination, medical history and physical examination, laboratory testing, level of care determination, and, if physiologic dependence is in doubt, a <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> challenge test.</p><p class="headingAnchor" id="H3249667807"><span class="h3">Substance use history</span><span class="headingEndMark"> — </span>A thorough<strong> </strong>substance use history of a potentially opioid-dependent patient should include:</p><p class="bulletIndent1"><span class="glyph">●</span>For each substance used, the amount used, frequency, route, duration, and time of last use. Duration of use influences the likelihood of physiologic dependence and withdrawal symptoms. The use of other substances along with opioids can influence the level of care needed and choice of subsequent maintenance medications. As an example, high risk for continued alcohol or benzodiazepine use may preclude the option to safely use <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>/<a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> for outpatient detoxification. (See <a class="local">'Course'</a> above and <a class="local">'Level of care determination'</a> below and  <a class="medical medical_review" href="/d/html/7808.html" rel="external">"Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of prior medically supervised withdrawal, medication used, complications, and response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior medication for opioid use disorder or other substance use disorder treatment: what worked and what did not. This will aid in determining initial planning for the postdetoxification period.</p><p></p><p class="headingAnchor" id="H289949301"><span class="h3">Psychiatric status, history, mental status examination</span><span class="headingEndMark"> — </span>Unless the subject is already in the throes of marked withdrawal when immediate action is needed, it is important to ascertain the patient's current mental status, as well as the patient’s history and current status of mental disorders, in particular, suicidality, anxiety, mood, psychotic, and trauma-related disorders, past treatment and response. Co-occurring mental disorders can be exacerbated by opioid withdrawal and may require symptomatic management with benzodiazepine, antipsychotic or other medications, or influence the needed level of care. (See <a class="local">'Co-occurring conditions'</a> above and <a class="local">'Level of care determination'</a> below.)</p><p>If the withdrawal is not managed by a psychiatrist, one should be consulted if active mental disorders are known or suspected. If the patient is on psychiatric medications, it is important to determine how these might impact supervised withdrawal. Noteworthy examples include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> levels can vary markedly with dehydration and must be monitored closely.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">Carbamazepine</a> may increase <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> dosing needs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychotropics strongly interacting with the CYP2D6 and 3A4 systems, such as <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a>, and <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, can affect levels of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> and, to a lesser extent, <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>. One might reduce starting doses of methadone by 50 percent and then follow symptom-guided dosing (balancing symptom control with side effects). For buprenorphine/naloxone, following symptom control/side effects alone is adequate to control for any needed dose adjustments.</p><p></p><p class="headingAnchor" id="H1845126588"><span class="h3">Medical history and physical examination</span><span class="headingEndMark"> — </span>Clinical priorities in taking a medical history and conducting a physical examination include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient history or physical examination finding symptoms/signs of cardiovascular disease (eg, congestive heart failure, hypertension or hypotension, and arrhythmias).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autonomic instability might reveal undisclosed alcohol or benzodiazepine dependence or infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History consistent with esophageal varices, blackouts, or falls due to vomiting should be elicited.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dehydration can commonly result from the gastrointestinal symptoms of opioid withdrawal, so if there are such signs prior to initiating the supervised withdrawal, or a history of frequent vomiting or severe diarrhea during supervised withdrawal, aggressive hydration (beyond encouraging oral intake) may be needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes can be complicated by poor oral intake during withdrawal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both liver and renal failure must be taken into account when choosing adjunctive medications targeting specific withdrawal symptoms. A table on adjunctive medications for opioid withdrawal symptoms indicates those to be avoided in the presence of renal or liver failure  (<a class="graphic graphic_table graphicRef106793" href="/d/graphic/106793.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Older patients are at elevated risk of dementia and/or delirium. Risk for delirium, in particular, is elevated in older adults with dementia; risk is also elevated in older adults with prior traumatic brain injury, medical illness, especially concurrent infection and hepatic insufficiency, dehydration/malnutrition, and current substance use disorders [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive impairment may increase the risk of agitation during supervised withdrawal. (See <a class="local">'Level of care determination'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some HIV medications affect levels of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> and, much less so, <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> [<a href="#rid32">32</a>]. Medication dosing in supervised withdrawal that is based on the severity of withdrawal symptoms and medication side effects, such as sedation and respiratory suppression, will control for these alterations. A brief summary is provided below:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All of the nonnucleoside reverse transcriptase inhibitors are metabolized by the liver and usually are CYP3A4 inducers. <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">Abacavir</a>, <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a>, and <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> may necessitate increased <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> dosing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The protease inhibitors are metabolized by the liver. While typically these are CYP3A4 inhibitors, some increase <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> renal clearance, necessitating increased dosing needs. <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">Ritonavir</a>, most ritonavir combinations, and <a class="drug drug_general" data-topicid="9685" href="/d/drug information/9685.html" rel="external">nelfinavir</a> might require higher dosing of methadone.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most of the nucleoside reverse transcriptase inhibitors undergo renal excretion, so they do not interact with <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>. An exception is <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a>, which may require methadone dosing increase.</p><p></p><p>The physical examination is an opportunity to engage the patient in medical care that in many cases has been ignored and to address potential physical consequences of opioid use, such as the presence of antecubital or other subcutaneous abscesses, cardiac murmur suggesting the presence of valve vegetation, signs of malnutrition, or signs of liver decompensation seen in hepatitis B/C infection or alcohol use disorder.</p><p>If withdrawal is not managed by an internist or primary care clinician, one should be consulted if clinically significant findings or potential complications are detected by medical history and physical examination.</p><p class="headingAnchor" id="H2733186750"><span class="h3">Laboratory and other testing</span><span class="headingEndMark"> — </span>Laboratory studies should include a complete blood count, a comprehensive metabolic profile including electrolytes, calcium and magnesium, glucose, liver and renal function tests; prothrombin time/partial thromboplastin time, HIV and hepatitis B/C screens, a urinalysis to rule out infection; and a urine drug screen, including ethyl glucuronide/ethyl sulfate and when not included in standard screening panels, specified tests for <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, <a class="drug drug_general" data-topicid="10010" href="/d/drug information/10010.html" rel="external">tramadol</a>, high-potency opioids such as <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>, and <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>. An electrocardiogram will assess QT/QTc, cardiac rhythm, and evidence of cardiac ischemia. Opioid-dependent women should be tested for pregnancy (with a negative result) prior to supervised withdrawal. (See  <a class="medical medical_review" href="/d/html/7808.html" rel="external">"Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"</a>.)</p><p class="headingAnchor" id="H3462363299"><span class="h3">Withdrawal symptoms</span><span class="headingEndMark"> — </span>A baseline assessment of the presence and severity of opioid withdrawal symptoms and signs is made upon the patient’s presentation using a standardized rating tool. Instrument selection is discussed separately. (See  <a class="medical medical_review" href="/d/html/7808.html" rel="external">"Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"</a>.)</p><p class="headingAnchor" id="H33544254"><span class="h3">Naloxone challenge test</span><span class="headingEndMark"> — </span>History and clinical evaluation using rating scales are usually sufficient to determine physiologic dependence. If dependence is uncertain, one can perform a <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> challenge test provided that pregnancy has been ruled out. A 0.2 mg dose of naloxone is administered intravenously or intramuscularly, or 0.8 mg subcutaneously. Withdrawal signs should appear 1 to 5 minutes after naloxone administration in an opioid-dependent patient. If no withdrawal is elicited after 5 minutes, administer 0.8 mg naloxone intravenously or intramuscularly or 3.2 mg subcutaneously, and observe for signs of withdrawal for another 20 minutes. The patient should be warned that withdrawal may occur quickly. They should also be reassured that the dose is sufficiently low and half-life is sufficiently short that resulting distress is typically minimal, especially if follow-up treatment for withdrawal symptoms is initiated quickly. (See  <a class="medical medical_review" href="/d/html/7808.html" rel="external">"Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"</a>.)</p><p>Precipitated withdrawal by this test can be serious and require more intensive medical management. For this reason, extended-release formulations or high doses of <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> are never used in the test [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H1615796051"><span class="h3">Level of care determination</span><span class="headingEndMark"> — </span>Patients withdrawing from opioids should be assessed for the level of care needed for medically supervised withdrawal. Treatment can be provided at several levels of care, including outpatient, intensive outpatient, partial hospital, residential (medically supervised) programs, or inpatient (medically managed) services. The best established system for assisting the clinician in determining the appropriate level of care is the American Society of Addiction Medicine (ASAM)'s Treatment Criteria [<a href="#rid34">34</a>]. In general, higher (or more intensive) levels of care are provided to patients with more severe and/or complex conditions, such as those with co-occurring medical disease or mental disorders. (See  <a class="medical medical_review" href="/d/html/7799.html" rel="external">"Substance use disorders: Determining appropriate level of care for treatment"</a>.)</p><p>The appropriate level of care for managing medically supervised withdrawal for a patient can be determined by applying the findings from the areas of assessment above to the first three dimensions of the ASAM criteria:</p><p class="bulletIndent1"><span class="glyph">●</span>Withdrawal potential</p><p class="bulletIndent1"><span class="glyph">●</span>Biomedical conditions and complications</p><p class="bulletIndent1"><span class="glyph">●</span>Emotional, behavioral, and cognitive conditions and complications</p><p></p><p>Examples of opioid-dependent patients requiring a higher level of care for medically supervised withdrawal include patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>A co-occurring mood, anxiety, or psychotic disorder; in contrast, patients with a trauma-related disorder, such as posttraumatic stress disorder, may have greater difficulty tolerating residential or inpatient care.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient with withdrawal-associated suicidality, confusion, or other cognitive impairment will often need inpatient care.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A need for dual supervised withdrawal from benzodiazepines, barbiturates, or alcohol as well as opioids, typically requiring close medical observation on a residential or inpatient unit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A history of congestive heart failure, hypertension or hypotension, or arrhythmia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients needing higher doses of an opioid agonist, for example, more than 12 mg/day of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> on day 1 or the maximum 40 mg/day 1 of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, generally require inpatient or residential care.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient with a recent history of recurrence of use at the prior, lower level of care.</p><p></p><p class="headingAnchor" id="H4005141208"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) diagnostic criteria for opioid withdrawal are as follows [<a href="#rid35">35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A. Presence of either of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>1. Cessation of (or reduction in) opioid use that has been heavy and prolonged (ie, several weeks or longer).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>2. Administration of an opioid antagonist after a period of opioid use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>B. Three (or more) of the following developing within minutes to several days after Criterion A:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dysphoric mood</p><p class="bulletIndent2"><span class="glyph">•</span>Nausea or vomiting</p><p class="bulletIndent2"><span class="glyph">•</span>Muscle aches</p><p class="bulletIndent2"><span class="glyph">•</span>Lacrimation or rhinorrhea</p><p class="bulletIndent2"><span class="glyph">•</span>Pupillary dilation, piloerection, or sweating</p><p class="bulletIndent2"><span class="glyph">•</span>Diarrhea</p><p class="bulletIndent2"><span class="glyph">•</span>Yawning</p><p class="bulletIndent2"><span class="glyph">•</span>Fever</p><p class="bulletIndent2"><span class="glyph">•</span>Insomnia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C. The signs or symptoms in Criterion B cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>D. The signs or symptoms are not attributable to another medical condition and are not better explained by another mental disorder, including intoxication or withdrawal from another substance.</p><p></p><p class="headingAnchor" id="H4094186483"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113643.html" rel="external">"Society guideline links: Opioid use disorder and withdrawal"</a>.)</p><p class="headingAnchor" id="H3121709317"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precipitants </strong>– Opioid withdrawal occurs when a patient with physiologic dependence on opioids reduces or stops using an opioid abruptly, or when an antagonist or partial agonist is administered to a patient with physiologic dependence. Untreated opioid withdrawal frequently results in recurrence of opioid use. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Symptoms and signs of unmedicated opioid withdrawal include (see <a class="local">'Clinical manifestations'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal distress – Abdominal cramps, diarrhea, nausea, and/or vomiting</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Flu-like symptoms – Lacrimation, rhinorrhea, diaphoresis, shivering, piloerection, and goose bumps</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sympathetic nerve and central nervous system arousal – Mydriasis, mild hypertension, and tachycardia, anxiety and irritability, insomnia, agitation, restless leg syndrome, general restlessness, tremor, and, less frequently, low-grade temperature and tactile sensitivity</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other – Yawning, sneezing, anorexia, dizziness, myalgias/arthralgias, leg cramps and dysthymia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Co-occurring conditions</strong> – Panic disorder and other anxiety disorders, mood disorders, suicidality, acute and posttraumatic stress disorder, and other substance use disorders are seen in greater frequency in patients with physiologic dependence on opioids. (See <a class="local">'Co-occurring conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Course </strong>– Following cessation of opioid use, the precise onset and completion of withdrawal, the order of symptoms, and their severity, varies among individuals and across opioid drugs [<a href="#rid36">36</a>]. Unmedicated opioid withdrawal can be quite uncomfortable but is rarely life threatening (see <a class="local">'Course'</a> above). A table describes times to onset and peak withdrawal, and duration of withdrawal for various opioids  (<a class="graphic graphic_table graphicRef105766" href="/d/graphic/105766.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment</strong> – We include an evaluation of each of the following in our assessment of individuals with opioid withdrawal (see <a class="local">'Initial evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Substance use history </strong>–<strong> </strong>We review substance use history thoroughly. The use of other substances along with opioids can influence the level of care needed and the choice of subsequent medication. Additionally, the duration of use can influence the likelihood of physiologic dependence and withdrawal symptoms. (See <a class="local">'Substance use history'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Psychiatry history and mental status </strong>– Unless the subject is already in marked withdrawal and needs immediate attention, we assess the individual’s current mental status with attention to suicidality, anxiety, psychosis, mood, and trauma-related disorders. (See <a class="local">'Psychiatric status, history, mental status examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medical history, physical examination, and laboratory testing </strong>– These are opportunities to engage the patient in medical care that in many cases has been ignored and to address potential physical consequences of opioid use. (See <a class="local">'Medical history and physical examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Withdrawal symptoms</strong> – A baseline assessment of the presence and severity of opioid withdrawal symptoms and signs is made upon the patient’s presentation using a standardized rating tool. (See <a class="local">'Withdrawal symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Naloxone</strong><strong> challenge test</strong> – History and clinical evaluation using rating scales are usually sufficient to determine physiologic dependence. If dependence is uncertain, one can perform a <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> challenge test provided that pregnancy has been ruled out. (See <a class="local">'Naloxone challenge test'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent treatment </strong>– As part of treatment planning, we include plans for transition to a maintenance treatment program for all individuals who have undergone medically supervised withdrawal. Supervised withdrawal alone does not generally result in sustained abstinence from opioids, and increases the risk of serious harms, including death. (See  <a class="medical medical_review" href="/d/html/7808.html" rel="external">"Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"</a>.)</p><p></p><p class="headingAnchor" id="H2764639355"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael Weaver, MD, and John Hopper, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Torres-Lockhart KE, Lu TY, Weimer MB, et al. Clinical Management of Opioid Withdrawal. Addiction 2022; 117:2540.</a></li><li><a class="nounderline abstract_t">Wines JD Jr, Saitz R, Horton NJ, et al. Overdose after detoxification: a prospective study. Drug Alcohol Depend 2007; 89:161.</a></li><li><a class="nounderline abstract_t">Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011; 106:32.</a></li><li><a class="nounderline abstract_t">Walley AY, Lodi S, Li Y, et al. Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis. Addiction 2020; 115:1496.</a></li><li><a class="nounderline abstract_t">Kanof PD, Aronson MJ, Ness R. Organic mood syndrome associated with detoxification from methadone maintenance. Am J Psychiatry 1993; 150:423.</a></li><li><a class="nounderline abstract_t">Mackie SE, McHugh RK, McDermott K, et al. Prevalence of restless legs syndrome during detoxification from alcohol and opioids. J Subst Abuse Treat 2017; 73:35.</a></li><li><a class="nounderline abstract_t">Nuamah JK, Sasangohar F, Erraguntla M, Mehta RK. The past, present and future of opioid withdrawal assessment: a scoping review of scales and technologies. BMC Med Inform Decis Mak 2019; 19:113.</a></li><li><a class="nounderline abstract_t">Ware OD, Dunn KE. Clinically meaningful individual differences in opioid withdrawal expression. Exp Clin Psychopharmacol 2023; 31:1005.</a></li><li><a class="nounderline abstract_t">Teoh Bing Fei J, Yee A, Habil MH. Psychiatric comorbidity among patients on methadone maintenance therapy and its influence on quality of life. Am J Addict 2016; 25:49.</a></li><li><a class="nounderline abstract_t">Fareed A, Eilender P, Haber M, et al. Comorbid posttraumatic stress disorder and opiate addiction: a literature review. J Addict Dis 2013; 32:168.</a></li><li><a class="nounderline abstract_t">Smart R, Kim JY, Kennedy S, et al. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder. J Subst Abuse Treat 2023; 144:108921.</a></li><li><a class="nounderline abstract_t">Goldner EM, Lusted A, Roerecke M, et al. Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: systematic review and meta-analyses. Addict Behav 2014; 39:520.</a></li><li><a class="nounderline abstract_t">Martins SS, Fenton MC, Keyes KM, et al. Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related Conditions. Psychol Med 2012; 42:1261.</a></li><li><a class="nounderline abstract_t">Jordan KD, Okifuji A. Anxiety disorders: differential diagnosis and their relationship to chronic pain. J Pain Palliat Care Pharmacother 2011; 25:231.</a></li><li><a class="nounderline abstract_t">Sullivan MD, Edlund MJ, Steffick D, Unützer J. Regular use of prescribed opioids: association with common psychiatric disorders. Pain 2005; 119:95.</a></li><li><a class="nounderline abstract_t">Johnston KJA, Huckins LM. Chronic Pain and Psychiatric Conditions. Complex Psychiatry 2023; 9:24.</a></li><li><a class="nounderline abstract_t">Scherrer JF, Salas J, Copeland LA, et al. Prescription Opioid Duration, Dose, and Increased Risk of Depression in 3 Large Patient Populations. Ann Fam Med 2016; 14:54.</a></li><li><a class="nounderline abstract_t">Sullivan MD, Edlund MJ, Zhang L, et al. Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med 2006; 166:2087.</a></li><li><a class="nounderline abstract_t">Wasan AD, Butler SF, Budman SH, et al. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain 2007; 23:307.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration. Substance Use Disorder Treatment for People With Co-Occurring Disorders. Treatment Improvement Protocol (TIP) Series, No. 42. SAMHSA Publication No. PEP20-02-01-004, Substance Abuse and Mental Health Services Administration; Department of Health and Human Services, Rockville, MD 2020.</li><li><a class="nounderline abstract_t">Mannelli P, Wu LT, Peindl KS, Gorelick DA. Smoking and opioid detoxification: behavioral changes and response to treatment. Nicotine Tob Res 2013; 15:1705.</a></li><li><a class="nounderline abstract_t">Stein MD, Kanabar M, Anderson BJ, et al. Reasons for Benzodiazepine Use Among Persons Seeking Opioid Detoxification. J Subst Abuse Treat 2016; 68:57.</a></li><li><a class="nounderline abstract_t">Bluthenthal RN, Simpson K, Ceasar RC, et al. Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs. Drug Alcohol Depend 2020; 211:107932.</a></li><li><a class="nounderline abstract_t">Kuramoto SJ, Chilcoat HD, Ko J, Martins SS. Suicidal ideation and suicide attempt across stages of nonmedical prescription opioid use and presence of prescription opioid disorders among U.S. adults. J Stud Alcohol Drugs 2012; 73:178.</a></li><li><a class="nounderline abstract_t">Herring AA, Perrone J, Nelson LS. Managing Opioid Withdrawal in the Emergency Department With Buprenorphine. Ann Emerg Med 2019; 73:481.</a></li><li><a class="nounderline abstract_t">Luba R, Jones J, Choi CJ, Comer S. Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance. Addiction 2023; 118:719.</a></li><li><a class="nounderline abstract_t">Sarcon A, Ghadri JR, Wong G, et al. Takotsubo cardiomyopathy associated with opiate withdrawal. QJM 2014; 107:301.</a></li><li><a class="nounderline abstract_t">Jain S, Singhai K, Swami M. Seizure as a primary presentation in opioid withdrawal. Psychiatry Clin Neurosci 2018; 72:802.</a></li><li><a class="nounderline abstract_t">Hanna J, Swetter S. A Case of Delirium and Rhabdomyolysis in Severe Iatrogenic Opioid Withdrawal. Psychosomatics 2018; 59:405.</a></li><li><a class="nounderline abstract_t">Wightman RS, Nelson LS, Lee JD, et al. Severe opioid withdrawal precipitated by Vivitrol®. Am J Emerg Med 2018; 36:1128.e1.</a></li><li><a class="nounderline abstract_t">Elie M, Cole MG, Primeau FJ, Bellavance F. Delirium risk factors in elderly hospitalized patients. J Gen Intern Med 1998; 13:204.</a></li><li><a class="nounderline abstract_t">Bruce RD, Moody DE, Altice FL, et al. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol 2013; 6:249.</a></li><li><a class="nounderline abstract_t">Fishman M. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction 2008; 103:1399.</a></li><li class="breakAll">ASAM: The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related and Co-Occurring Conditions, 3rd ed, Mee-Lee D, Shulman GD, Fishman MJ, et al (Eds), The Change Companies, Carson City 2013.</li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</li><li class="breakAll">Vaughan BR, Kleber HD. Opioid detoxification, chap. 20. In: American Psychiatric Press Textbook of Substance Abuse Treatment, 5th ed, Galanter M, Kleber HD, Brady KT (Eds), American Psychiatric Publishing, Washington DC 2015.</li></ol></div><div id="topicVersionRevision">Topic 105686 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35112746" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical Management of Opioid Withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17280803" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Overdose after detoxification: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21054613" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32096908" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8434657" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Organic mood syndrome associated with detoxification from methadone maintenance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28017182" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of restless legs syndrome during detoxification from alcohol and opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31215431" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The past, present and future of opioid withdrawal assessment: a scoping review of scales and technologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37166910" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinically meaningful individual differences in opioid withdrawal expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26692463" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Psychiatric comorbidity among patients on methadone maintenance therapy and its influence on quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23815424" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comorbid posttraumatic stress disorder and opiate addiction: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36327615" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24333033" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: systematic review and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21999943" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21882977" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Anxiety disorders: differential diagnosis and their relationship to chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16298066" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Regular use of prescribed opioids: association with common psychiatric disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37034825" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chronic Pain and Psychiatric Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26755784" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prescription Opioid Duration, Dose, and Increased Risk of Depression in 3 Large Patient Populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060538" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Association between mental health disorders, problem drug use, and regular prescription opioid use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17449991" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17449991" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23572466" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Smoking and opioid detoxification: behavioral changes and response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27431047" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Reasons for Benzodiazepine Use Among Persons Seeking Opioid Detoxification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32199668" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22333325" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Suicidal ideation and suicide attempt across stages of nonmedical prescription opioid use and presence of prescription opioid disorders among U.S. adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30616926" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Managing Opioid Withdrawal in the Emergency Department With Buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36444486" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24170890" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Takotsubo cardiomyopathy associated with opiate withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30062724" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Seizure as a primary presentation in opioid withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29325983" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A Case of Delirium and Rhabdomyolysis in Severe Iatrogenic Opioid Withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29605483" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Severe opioid withdrawal precipitated by Vivitrol®.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9541379" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Delirium risk factors in elderly hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23656339" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18855831" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
